ATG-Fresenius S is a concentrated anti-human T-lymphocyte immunoglobulin preparation derived from rabbits after immunization with a T-lympoblast cell line. ATG-Fresenius S is an immunosuppressive product for the prevention and treatment...
- Mechanism
- Curator reviewed
ATG-Fresenius S works by selective suppression of activated cells, which are responsible for the rejection of transplanted organs. Transplant rejection occurs when the immune system of the patient attacks the newly transplanted organ or tissue from another donor. Rejection occurs because a normal healthy human immune system can distinguish foreign tissues and attempts to destroy them.
- Primary indication
- Investigated for use/treatment in immunosuppressive and transplant (rejection).Curator reviewed
What you can answer from here — as of April 02, 2025
Which companies are running trials of ATG-Fresenius S, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account